John Tisdale

Branch Chief

National Institutes of Health

United States

Research Interests

Explore related searches

Professors in United States Professors in Tissue Engineering Tissue Engineering professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

John Tisdale serves as the Branch Chief at the National Institutes of Health in the United States. His research focuses primarily on gene therapy and stem cell transplantation, particularly in relation to sickle cell disease. Recent publications highlight advancements in gene therapy, clinical trials, and innovative treatment approaches for patients suffering from this condition.

Articles (9)

Year:

2025

Year:

2024

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

SWEE LAY THEIN

Senior Investigator/ Branch Chief

National Institutes of Health

UNITED STATES

View details

Alexis Thompson

Division Chief

Children's Hospital of Philadelphia

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

John Tisdale

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Gene therapy for sickle cell disease: recent advances, clinical trials and future directions

A new frontier: FDA approvals for gene therapy in sickle cell disease

Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease

Increased Rates of Rhabdomyolysis in Male Hematopoietic Cell Transplantation Recipients Taking Sirolimus and Trimethoprim/Sulfamethoxazole

Gene therapy for sickle cell disease: moving from the bench to the bedside

Dietary iron restriction improves markers of disease severity in murine sickle cell anemia

Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi‐center HGB‐206 trial

Intrabone transplantation of CD34+ cells with optimized delivery does not enhance engraftment in a rhesus macaque model

Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?

Collaborators (2)

SWEE LAY THEIN

Alexis Thompson

Make your next move.